Seres Therapeutics (NASDAQ:MCRB) Earns “Buy” Rating from Canaccord Genuity Group

Canaccord Genuity Group reaffirmed their buy rating on shares of Seres Therapeutics (NASDAQ:MCRB) in a research note issued to investors on Thursday morning,Benzinga reports. They currently have a $10.00 target price on the biotechnology company’s stock.

Several other equities research analysts have also recently issued reports on the company. JPMorgan Chase & Co. cut Seres Therapeutics from a “neutral” rating to an “underweight” rating in a report on Thursday, October 24th. StockNews.com cut Seres Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 13th. Finally, Chardan Capital restated a “buy” rating and set a $1.25 target price on shares of Seres Therapeutics in a research report on Wednesday, November 13th. Two analysts have rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $5.08.

Seres Therapeutics Trading Down 7.2 %

Shares of MCRB stock opened at $0.55 on Thursday. Seres Therapeutics has a 12-month low of $0.54 and a 12-month high of $2.05. The stock’s 50-day moving average price is $0.85 and its 200-day moving average price is $0.91. The stock has a market capitalization of $93.85 million, a price-to-earnings ratio of -2.39 and a beta of 2.06.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the business. Providence Wealth Advisors LLC boosted its position in shares of Seres Therapeutics by 29.2% during the third quarter. Providence Wealth Advisors LLC now owns 98,500 shares of the biotechnology company’s stock valued at $93,000 after buying an additional 22,250 shares during the period. State Street Corp boosted its holdings in shares of Seres Therapeutics by 12.9% in the third quarter. State Street Corp now owns 383,248 shares of the biotechnology company’s stock valued at $363,000 after purchasing an additional 43,700 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Seres Therapeutics in the first quarter valued at approximately $39,000. Point72 DIFC Ltd purchased a new stake in shares of Seres Therapeutics in the second quarter valued at approximately $64,000. Finally, Virtu Financial LLC purchased a new stake in shares of Seres Therapeutics in the first quarter valued at approximately $73,000. Hedge funds and other institutional investors own 59.34% of the company’s stock.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.